Please ensure Javascript is enabled for purposes of website accessibility

Here's Why TherapeuticsMD Stock Is Rocketing Higher Today

By Cory Renauer - Apr 29, 2020 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A newly issued patent could provide market exclusivity for its long-term contraceptive device.

What happened

Shares of TherapeuticsMD (TXMD 0.10%), a women's healthcare company, are on the rise following good news for its contraceptive device Annovera. Investors expecting more predictable cash flows have driven the stock 56% higher as of 1:06 p.m. EDT on Tuesday.

So what 

Annovera's a reusable contraceptive ring that contains two synthetic hormones -- segesterone acetate and ethinyl estradiol -- that prescription contraceptives have been using for a long time. Annovera remains inserted for three weeks and releases these two ingredients slowly before women need to remove and store the device for a week.

Arrow shooting higher on a blue background.

Image source: Getty Images.

Annovera earned Food and Drug Administration (FDA) approval for its yearlong birth-control device in 2018, but so far, the launch has been slow. Sales of the contraceptive reached an annualized $23 million in the fourth quarter of 2019, which worked out to 36% of TherapeuticsMD's total revenue during the period.

Now what

Each Annovera ring is approved to be reused for an entire year's worth of four-week cycles, and this prescription contraceptive tool from TherapeuticsMD will probably be the only one that can make this claim for years to come. The newly issued patent provides U.S. patent protection for Annovera until 2039.

At the very least, it will allow TherapeuticsMD to keep potential competitors tied up in court for years while sales of the contraceptive keep rising. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
TXMD
$9.93 (0.10%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.